SHERIDAN, WYOMING – May 5, 2025 – Johnson & Johnson MedTech has announced the presentation of 22 sponsored or funded clinical studies at the Heart Rhythm Society (HRS) 2025 Annual Meeting in San Diego, showcasing its continued leadership in the electrophysiology space. The company’s expansive dataset highlights innovation in pulsed field ablation (PFA) technologies, real-world treatment strategies, and critical insights from the REAL-AF Registry and Patient Care Pathways and Outcomes study—reinforcing its commitment to evidence-based care and better patient outcomes.
Driving Strategic Innovation in Cardiac Electrophysiology
The studies presented span the full breadth of Johnson & Johnson MedTech’s electrophysiology portfolio, addressing atrial fibrillation (AFib) diagnosis, integrated PFA platforms, and clinical outcomes. These data reflect the company’s strategic priority to drive safe, effective, and efficient cardiac ablation solutions that meet rising global demand.
“As rising clinical demand accelerates the need for safe, effective and efficient cardiac ablation solutions, Johnson & Johnson MedTech is proud to advance evidence-driven innovation that meets the evolving needs of physicians and patients worldwide,” said Jasmina Brooks, President, Electrophysiology, Johnson & Johnson MedTech.
Brooks emphasized the company’s focus on collaborative research, including its support for landmark studies such as the REAL-AF Registry and the Patient Care Pathways and Outcomes study, which explore guideline adherence and treatment optimization for newly diagnosed AFib patients.
Clinical Highlights and Research Milestones
The 22 studies unveiled at HRS 2025 reinforce Johnson & Johnson MedTech’s leading role in advancing next-generation electrophysiology technologies. Notable presentations include:
- Late-Breaking Data: Omny-IRE 3-Month First-in-Human results, evaluating the safety, efficacy, and PVI durability of a contact force-sensing large-tip focal PFA catheter integrated with 3D mapping.
- Prospective Validation: New ablation index predicting lesion depth during PFA based on contact force and number of applications.
- REAL-AF Registry Insights: Real-world data on sex differences in ablation strategies and clinical outcomes.
- Care Pathways Focus: Findings on patient outcomes following new AFib diagnosis, underscoring the importance of clinical guidelines.
- Learning Curve Evaluation: Safety profile and procedural adoption of a variable loop circular PFA catheter from a multicenter postmarket trial.
This robust slate of clinical data builds upon recent findings shared at the European Heart Rhythm Association (EHRA) Annual Meeting, including 12-month SmartfIRE trial results, further solidifying the company’s role in transforming AFib care pathways.
Supporting the Electrophysiology Community
Beyond data presentations, Johnson & Johnson MedTech is actively contributing to physician education at HRS 2025 through:
- On-site training and in-booth presentations
- Scientific programs aimed at improving procedural technique
- Recognition of innovation with the prestigious 2025 Will Webster Lectureship Award, honoring transformative contributions to cardiac electrophysiology
These initiatives reflect the company’s broader commitment to investing in the global electrophysiology community and enhancing care quality through knowledge sharing and collaborative advancement.
Strategic Positioning in a Dynamic Healthcare Market
Johnson & Johnson MedTech’s cardiovascular portfolio spans advanced mapping and navigation, miniaturized technology, and precision ablation—addressing major global health burdens such as atrial fibrillation, heart failure, stroke, and coronary artery disease.
As a recognized global leader in heart rhythm management and an emerging force in neurovascular care, the company is strategically positioned to lead innovation in high-growth, high-need segments of MedTech.
Looking Ahead
With its latest research efforts and deepening partnerships across the electrophysiology ecosystem, Johnson & Johnson MedTech continues to drive the next chapter in arrhythmia care—enabling more precise interventions, improving outcomes, and shaping the future of cardiac healthcare.